Trigeminal neuralgia (NTN) is a chronic condition characterized by acute pain attacks in the distribution of the trigeminal nerve (cranial nerve V). The pain is sharp, shooting, and may occur spontaneously or be triggered by mechanical stimuli such as touching the face, chewing, or even a slight breeze. Trigeminal neuralgia most often occurs in patients over 50 years of age, but can also occur in younger people. The disease may be a manifestation of various pathophysiological processes, including nerve compression, multiple sclerosis, or tumor processes.
History of the disease and interesting historical facts
Descriptions of trigeminal neuralgia date back to ancient times, when physicians sought to understand the nature of facial pain. Trigeminal neuralgia, or paralysis, was mentioned in the writings of Hippocrates and Avicenna, indicating a long history of study of the condition. In the 19th century, neuralgia began to be studied more systematically, when physicians began to identify it as a distinct disorder. One of the landmark moments in the history of NTN was a study in the 1820s by physician John Houston, who recommended surgery to relieve symptoms. In the 1940s, neurosurgical techniques, including deaeration, began to evolve, offering new approaches to treatment. Recent decades have seen a resurgence of interest in trigeminal neuralgia, due to new diagnostic and therapeutic options, as well as an improved understanding of the pathophysiology of the disorder.
Epidemiology
Trigeminal neuralgia has certain epidemiological characteristics. There is evidence that the incidence rate is about 4-5 cases per 100,000 population per year. The disease is more common in women than in men, with a ratio of 3:1. The age groups most susceptible to NTN are patients over 50 years of age, although cases in younger people have also been reported. As a result of research, it was found that about 0.3% of the population suffers from trigeminal neuralgia, and in the age group of 70 years and older, this figure can increase to 7%.
Genetic predisposition to this disease
Despite the considerable attention paid to the medical aspects of trigeminal neuralgia, the genetic basis of this condition is poorly understood. To date, there is no clear evidence that NTN is a hereditary disorder. However, some studies point to a possible role for certain genes and mutations, particularly those involved in the metabolism of neurotransmitters such as serotonin and dopamine. Studies of chromosomes 17 and 22 have identified potential regions involved in susceptibility to neuralgia. Genetic dysfunction may affect myelination and synaptic transmission, potentially predisposing to NTN.
Risk factors for the development of this disease
There are various risk factors that may contribute to the development of trigeminal neuralgia. These include:
- Age: The majority of cases occur in patients over 50 years of age.
- Gender: Women are more likely to suffer from NTN.
- Presence of vascular diseases. They can be considered as predisposing to compression of the trigeminal nerve.
- Multiple sclerosis and other demyelinating diseases. They can cause damage to the myelin sheath of the nerve and lead to pain syndromes.
- Head and facial trauma. This can lead to nerve damage.
- Genetic predisposition. In rare cases, the disease may run in families.
Diagnosis of this disease
Diagnosis of trigeminal neuralgia is based on history taking and clinical examination. The main symptoms include:
- Paroxysmal pain on one side of the face, cerebrovascular activation.
- Sharp, shooting, or stabbing pain that can last from a few seconds to several minutes.
- Uncontrollable response to mild stimuli.
Laboratory tests may include:
- Complete blood count (ESR, plasma protein level).
- Immunological tests to detect demyelinating processes.
Radiological examinations such as magnetic resonance imaging (MRI) are used to detect possible structural changes, including compression of the nerve by tumors or aneurysms. In addition to these methods, electroneuromyography (ENMG) may be useful in some cases to evaluate trigeminal nerve function and exclude other conditions. Differential diagnosis includes conditions such as toothache, migraine, and other types of neuralgia.
Treatment
Treatment of trigeminal neuralgia involves several approaches. The main treatment consists of:
- Pharmacological treatment.
- Surgical intervention.
- Physiotherapy.
- Psychotherapy.
Pharmacological treatment mostly includes:
- Anticonvulsants (carbamazepine, oxcarbazepine).
- Neuroleptics and antidepressants in resistant cases.
- Trigeminal nerve block with anesthetics for temporary relief of symptoms.
Surgical treatment is indicated in cases where drug therapy is ineffective. This may include trigeminal nerve decompression surgery or radiosurgery.
List of medications used to treat this disease
The following medications can be used to treat trigeminal neuralgia:
- Carbamazepine
- Oxycarbazepine
- Gabapentin
- Pregabalin
- Depressants (amitriptyline, etc.)
- Bupivocaine for blockades
Disease monitoring
Monitoring of trigeminal neuralgia involves regular visits to the doctor to assess the patient's condition, adjust treatment, and evaluate the effectiveness of therapy. The prognosis is favorable in most cases, but the disease may be recurrent. Complications, including the development of chronic pain or drug dependence, may also require serious attention.
Age-related features of the disease
Trigeminal neuralgia presents differently depending on age group. In older people, the condition is more often associated with comorbidities such as diabetes or hypertension. In younger patients, NTN can present more aggressively and often requires less invasive treatments.
Questions and Answers
- What are the main symptoms of trigeminal neuralgia? The main symptoms are sharp, shooting pains in the face, which can be provoked by light touches, chewing or talking.
- What treatment methods exist to neutralize pain? Treatment may include the use of anticonvulsants, trigeminal nerve blocks, and surgical procedures if conservative therapy is ineffective.
- Does trigeminal neuralgia affect quality of life? Yes, this disease can significantly reduce the quality of life, causing constant or episodic pain and limiting daily activities.
- What are the risk factors for developing this disease? Risk factors include age, gender, history of vascular disease, and head and facial injuries.
- Is there a chance of relapse after treatment? Yes, there is a possibility of relapse, especially if the disease is caused by structural changes or concomitant diseases.
